NUVB Profile
Nuvation Bio Inc., a clinical-stage biopharmaceutical company headquartered in New York, is dedicated to advancing innovative therapeutic candidates for oncology. Founded in 2018 and previously known as RePharmation Inc., the company focuses on developing next-generation cancer treatments through targeted small molecule inhibitors and novel drug delivery platforms. Its mission is to address unmet medical needs in cancer therapy by leveraging cutting-edge science and technology.
The company's flagship candidate, NUV-422, is a small molecule inhibitor designed to target cyclin-dependent kinases (CDK) 2, 4, and 6, which are crucial in regulating cell cycle progression and tumor growth. NUV-422 is aimed at treating a range of cancers where dysregulation of these CDKs plays a significant role. In addition, Nuvation Bio is developing NUV-868, a selective oral small molecule inhibitor of BET proteins that are involved in the epigenetic regulation of tumor growth and differentiation, offering a novel approach to cancer treatment.
Nuvation Bio's pipeline also includes NUV-569, a selective inhibitor of the Wee1 kinase, which plays a critical role in DNA damage repair. By targeting this pathway, NUV-569 aims to enhance the effectiveness of existing cancer therapies and improve outcomes for patients. The company is also advancing NUV-1182, an adenosine receptor inhibitor, which is expected to modulate the immune microenvironment and support anti-tumor immunity.
In addition to its core drug development programs, Nuvation Bio is exploring a drug-drug conjugate (DDC) platform. This platform focuses on linking poly ADP ribose polymerase (PARP) inhibitors to anti-cancer agents, potentially offering enhanced efficacy in treating ER+ breast and ovarian cancers. Through its comprehensive approach to drug discovery and development, Nuvation Bio aims to deliver transformative therapies that address critical challenges in oncology and improve patient outcomes.
|
